BACKGROUND: We conducted a phase II clinical trial of induction chemotherapy followed by surgery ± radiotherapy for squamous cell carcinoma of the oral tongue (SCCOT) in young adults. METHODS: From September 2001 to October 2004, 23 patients aged 18 to 49 years with clinical T2-3 N0-2 M0 SCCOT and no prior radiotherapy, chemotherapy, or neck dissection underwent induction chemotherapy (paclitaxel, ifosfamide, and carboplatin) followed by glossectomy and neck dissection ± radiotherapy and chemotherapy. RESULTS: On final surgical pathology, 9 patients (39%) had a complete/major (2 complete) histologic response at the primary tumor site; 8 patients (35%) had no response or progression. Similarly, 9 patients (39%) had a complete response in the neck or remained node negative; 6 patients (26%) had an increase in nodal category. No treatment-associated deaths occurred, and toxicity was modest. At a median follow-up from the end of treatment of 52 months (minimum, 23 months), 10 patients (43%) developed recurrence, and all 10 died of cancer. Crude recurrence/cancer death rates were associated with ≤ a partial response at the tongue (p = .029), poor histologic differentiation (p = .012), and multiple adverse features on final surgical pathology (p = .040). CONCLUSION: Response rates and overall survival with this induction chemotherapy regimen were limited, but complete/major response at the tongue was associated with excellent prognosis. Additionally, improved patient selection and predictive tumor biomarkers will be needed for induction chemotherapy to be routinely incorporated into the treatment of oral tongue cancer in young adults.
BACKGROUND: We conducted a phase II clinical trial of induction chemotherapy followed by surgery ± radiotherapy for squamous cell carcinoma of the oral tongue (SCCOT) in young adults. METHODS: From September 2001 to October 2004, 23 patients aged 18 to 49 years with clinical T2-3 N0-2 M0 SCCOT and no prior radiotherapy, chemotherapy, or neck dissection underwent induction chemotherapy (paclitaxel, ifosfamide, and carboplatin) followed by glossectomy and neck dissection ± radiotherapy and chemotherapy. RESULTS: On final surgical pathology, 9 patients (39%) had a complete/major (2 complete) histologic response at the primary tumor site; 8 patients (35%) had no response or progression. Similarly, 9 patients (39%) had a complete response in the neck or remained node negative; 6 patients (26%) had an increase in nodal category. No treatment-associated deaths occurred, and toxicity was modest. At a median follow-up from the end of treatment of 52 months (minimum, 23 months), 10 patients (43%) developed recurrence, and all 10 died of cancer. Crude recurrence/cancer death rates were associated with ≤ a partial response at the tongue (p = .029), poor histologic differentiation (p = .012), and multiple adverse features on final surgical pathology (p = .040). CONCLUSION: Response rates and overall survival with this induction chemotherapy regimen were limited, but complete/major response at the tongue was associated with excellent prognosis. Additionally, improved patient selection and predictive tumor biomarkers will be needed for induction chemotherapy to be routinely incorporated into the treatment of oral tongue cancer in young adults.
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Erich M Sturgis; Brian A Moore; Bonnie S Glisson; Merrill S Kies; Dong M Shin; Robert M Byers Journal: Head Neck Date: 2005-09 Impact factor: 3.147
Authors: André Lopes Carvalho; Inês Nobuko Nishimoto; Joseph A Califano; Luiz Paulo Kowalski Journal: Int J Cancer Date: 2005-05-01 Impact factor: 7.396
Authors: Susan Furness; Anne-Marie Glenny; Helen V Worthington; Sue Pavitt; Richard Oliver; Jan E Clarkson; Michaelina Macluskey; Kelvin Kw Chan; David I Conway Journal: Cochrane Database Syst Rev Date: 2010-09-08
Authors: F Christopher Holsinger; Merrill S Kies; Eduardo M Diaz; Ann M Gillenwater; Jan S Lewin; Lawrence E Ginsberg; Bonnie S Glisson; Adam S Garden; Nebil Ark; Heather Y Lin; J Jack Lee; Adel K El-Naggar; Waun Ki Hong; Dong M Shin; Fadlo R Khuri Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Federica Perrone; Paolo Bossi; Barbara Cortelazzi; Laura Locati; Pasquale Quattrone; Marco A Pierotti; Silvana Pilotti; Lisa Licitra Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544
Authors: Abdullah A Osman; David M Neskey; Panagiotis Katsonis; Ameeta A Patel; Alexandra M Ward; Teng-Kuei Hsu; Stephanie C Hicks; Thomas O McDonald; Thomas J Ow; Marcus Ortega Alves; Curtis R Pickering; Heath D Skinner; Mei Zhao; Eric M Sturgis; Merrill S Kies; Adel El-Naggar; Federica Perrone; Lisa Licitra; Paolo Bossi; Marek Kimmel; Mitchell J Frederick; Olivier Lichtarge; Jeffrey N Myers Journal: Cancer Res Date: 2015-02-17 Impact factor: 12.701
Authors: Marta Tagliabue; Pietro Belloni; Rita De Berardinis; Sara Gandini; Francesco Chu; Stefano Zorzi; Caterina Fumagalli; Luigi Santoro; Susanna Chiocca; Mohssen Ansarin Journal: Cancer Med Date: 2021-03-24 Impact factor: 4.452